This is because, in the majority of BRCA1 carriers, breast tumors have distinctive morphologic features and immunohistochemical phenotypes characteristic of basal-like breast cancers, including negative expression of the estrogen receptor, high expression of basal markers, such as basal cytokeratins CK5/6 and CK14, and loss of tumor-suppressor PTEN [6-8]. This evidence concerns the gene BRCA1 and neoplasm.